CSL Ltd Annual Report 2020

Business performance and highlights ^ Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further detail please refer to page 16. * Does not include Ruide. Limited assurance by Ernst & Young. More on CSL.com (Investors and Our Company > Corporate Responsibility) • Another strong year with revenue up 9% ^ and reported net profit after tax of US$2,103 million, up 17% at constant currency (CC) ^ . • Our largest franchise, the immunoglobulin portfolio, performed extremely well, with PRIVIGEN ® sales growing 20% ^ and HIZENTRA ® sales up 34% ^ . • Seqirus’ earnings before interest and taxes grewmore than 70% this year underpinned by sales of new and differentiated products – FLUCELVAX ® and FLUAD ® . • Major capital projects underway at all manufacturing sites to support future demand. • 40 new plasma collection centres opened in the United States (US). • Strategic review of end-to-end supply logistics. • Strategic partnership with Thermo Fisher Scientific for lease of CSL’s Lengnau, Switzerland, biotech manufacturing facility. • Direct distribution transition in China now complete. • Underwent 401 regulatory inspections of our manufacturing facilities* with no impact to licences or operations. • Total revenue up 11% at CC basis driven by our seasonal influenza vaccines, with a significant increase in demand for FLUAD, Seqirus’ adjuvanted influenza vaccine for the elderly market and increased sales of FLUCELVAX ® Quadrivalent influenza vaccine. • Acquired Vitaeris to expedite the development of Clazakizumab – an anti-interleukin-6 monoclonal antibody for the treatment of chronic antibody-mediation rejection (or AMR) in kidney transplant recipients. • Agreement to acquire the late stage gene therapy candidate for the treatment of haemophilia B from uniQure. • Futility test for CSL112 was completed with the recommendation that the trial should continue (currently in Phase III for cardiovascular disease). • Achieved 29 product registrations or new indications in numerous countries. • CSL named in Best Employers for Diversity (Forbes). • Employee workforce up 7% , with 57% of our employee base female. • Achieved 76% employee engagement score, up 2.4 points on prior year. • US$8.8 billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions. • US$38.7 million in global community investment across our strategic areas of support. Efficiency Efficiency Influenza Influenza Innovation Innovation People & culture People & culture Shared value Shared value Growth Sustainable Growth CSL Limited Annual Report 2020 6 2020 Performance 2